Home
Overview
Results of the early benefit assessment
G-BA procedures
Resolutions
Subpopulations
Patients
Indication areas (G-BA)
Eye diseases
Skin diseases
Cardiovascular diseases
Infectious diseases
Respiratory system diseases
Hematopoietic diseases
Musculoskeletal system diseaeses
Nervous system diseases
Genitourinary system diseases
Digestive system diseases
Oncological diseases
Mental illnesses
Other diseases
Metabolic diseases
Orphan Drugs
Special constellations
Orphan drugs
ATMP
ATMP CAR-T cells
PUMA
Evidence transfer
Reserve antibiotics
Conditional marketing authorisation
Approval under exceptional circumstances
Accelerated assessment
New data protection
Procedures without a dossier
Results of reassessments
Limitation
G-BA request (§13 VerfO)
Manufacturer's request (§14 VerfO)
Orphan drugs, exceeding turnover limit
Orphan drugs, loss of status
G-BA requirements
Accompanying data collection (AbD)
Quality requirements for ATMP
Bundling
Repealed resolutions
Procedures
G-BA resolutions
G-BA active procedures
G-BA procedures not completed
EMA CHMP positive opinions
Reimbursement prices
Recent price changes
Arbitration results
Discontinuations
Special practice conditions
AM-RL Appendix III: Prescription exclusions
AM-RL Appendix VI: Off-label Use
AM-RL Appendix VIIa: Biosimilars
AM-RL Appendix XIIa: Combination discounts
Interactive Analysis
Resolutions
Subpopulations
All Procedures (active+resolutions)
Intelligent search
EU HTA
European cooperation
Legal basis
Parallel Scientific Advice
Scoping process
Methods
Implementation timeline
Dossier structure
EU-HTA and G-BA/IQWiG
Fundamentals
AMNOG Monitor step by step
Detailed analysis for each G-BA resolution
Interactive analysis
Interactive analysis: Excel export
Interactive analysis: Bookmarks
Interactive analysis: dimensions
Intelligent search
Monthly report
AMNOG Monitor app
Calculation methods
EMA regulatory procedure
Changes in legal regulations
Technical terms English-German
Contact
Contact form
Legal notice
Privacy policy
Search G-BA resolutions
Login
Login
Username
Password
G-BA resolutions
G-BA active procedures
G-BA procedures not completed
EMA CHMP positive opinions
Currently active benefit assessment procedures persuant to art. 35a SGB V
